⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 19, 2019Annals of the Rheumatic DiseasesOpen Access

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

ClinicalTrials.gov Registries (NCT02465580 and NCT02932137).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

He et al. (2019) studied this question.

synapsesocial.com/papers/69db1b6f1e19c8ae0883627b https://doi.org/10.1136/annrheumdis-2019-215396

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host DiseaseOriginal Research · 2013 · 474 citations
2Phenotype and function of natural killer cells in systemic lupus erythematosus: Excess interferon-γ production in patients with active diseaseOriginal Research · 2011 · 147 citations
3Recognition and Regulation of T Cells by NK CellsReview · 2016 · 172 citations
4Insufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cellsReview · 2016 · 20 citations
5The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: Measures of overall disease activityHuman Clinical Trial · 2004 · 138 citations